SCHEMBL2564598

SCHEMBL2564598

CCOC(=O)C1CCC(c2ncccc2N)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.46
LGMN Q99538 1/20 0.44
POLB P06746 1/20 0.43
CTSB P07858 1/20 0.43
CHRM4 P08173 1/20 0.42
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
ELANE P08246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12238776 1.00 CYP2C19 (0.49) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL2546555 0.85 CYP2C19 (0.49) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL2546557 0.85 CYP2C19 (0.49) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL2543459 0.82 CYP2C19 (0.49) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL2543462 0.82 CYP2C19 (0.49) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL2542196 0.80 ALDH1A1 (0.43) CYP2C19ALDH1A1KDM4EKMT2AMAPT
SCHEMBL2542198 0.80 ALDH1A1 (0.43) CYP2C19ALDH1A1KDM4EKMT2AMAPT
SCHEMBL16803157 0.80 ABL1 (0.44) CYP2C19KDM4EL3MBTL1POLBCHRM4
SCHEMBL2560479 0.79 CYP2C19 (0.50) CYP2C19ALDH1A1KDM4EKMT2ATP53
SCHEMBL3435703 0.78 MAPT (0.57) CYP2C19ALDH1A1KDM4EKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492376-B2 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-07-23 US disclosed
WO-2011131596-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-27 WO disclosed
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-10-27 US disclosed
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AVPR1A, AVPR1B, OXTR CYP2C19 225/4885ALDH1A1 682/4885KDM4E 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.